Elikya Therapeutics is a biotechnology start-up developing new generation of Antibody Drug Conjugates (ADCs) in oncology using its proprietary and first-in-class toxic payloads. The company is a spin-off of the University Paris Saclay, France (UPS) and the Gustave Roussy Institute (IGR) in France. Through its academic founders, Elikya Therapeutics is leveraging more than 15 years of world recognized research. The team is also composed of seasoned team of biotech industrials with more than 35 years of experience in the biotech and pharma industry. The company has been incorporated in December 2021, and currently is hosted at the incubator, Quest for Health (SEMIA) in Strasbourg, France. Elikya Therapeutics is focused on the development of First-in-Class toxic payloads for ADC and intra-tumoral therapies with differentiated mechanism of action against cancer cells and tumoral micro-environment.
11 Rue de l'Académie, 67000 Strasbourg
Fondée en 2021
Adhérents depuis 2024